Pediatric Vaccines Market – By Type (Monovalent, Multivalent), Technology (Live Attenuated, Inactivated, Conjugate, Toxoid), Indication (Influenza, Human Papilloma Virus, Polio, DPT), End-use (Public, Private) Global Forecast (2024 – 2032)

Pediatric Vaccines Market Size

Pediatric Vaccines Market size was valued at USD 48.1 billion in 2023 growing at a CAGR of 8.9% from 2024 and 2032, due to rising prevalence of infectious and chronic disease among children. The outbreaks of diseases such as measles, mumps, and rubella create an urgent need for vaccination.
 

For instance, as per the report published by World Health Organization in April 2024, it has been reported that there were an estimated 136,000 measles deaths globally, mostly among unvaccinated or under vaccinated children under the age of 5 years. Similarly, in 2022, 74% of children received both doses of the measles vaccine, and about 83% of the world's children received one dose of measles vaccine by their first birthday. Thus, the increasing prevalence of chronic and infectious disease and rise in awareness and education about the importance of vaccination among parents and caregivers lead to higher uptake rates, thereby contributing to the market growth.
 

A pediatric vaccine is a vaccine designed to protect infants, and children from various infectious diseases. These vaccines are formulated to be safe and effective for younger populations and are typically administered according to a recommended immunization schedule. Pediatric vaccines help prevent diseases such as measles, mumps, rubella, polio, diphtheria, tetanus, pertussis (whooping cough), hepatitis, influenza, and more. They play a crucial role in promoting public health by reducing the incidence of these diseases and preventing outbreaks.
 

Pediatric Vaccines Market Trends

The rising prevalence of infectious and chronic disease in children significantly fuels the growth of the market. Infectious diseases such as measles, mumps, rubella, and pertussis pose serious health threats to children, driving demand for vaccines to prevent these illnesses and curb potential outbreaks.
 

• For instance, as per the report published by National Foundation for Infectious Disease in September 2023, it is estimated that an average of 20,000 children under the age of 5 are hospitalized due to flu complications each year. Thus, the rising prevalence of infectious disease globally increases the demand for pediatric vaccines that will boost the market for pediatric vaccines.
   

Further, increased awareness and education pertaining to the benefits of vaccination in preventing complications associated with these diseases contribute to higher vaccination rates and sustained market growth.
 

Pediatric Vaccines Market Analysis

Based on the type, the market is classified into monovalent vaccines and multivalent vaccines. The multivalent vaccines segment dominated the market with revenue of USD 30 billion in 2023.
 

• Multivalent vaccines protect against multiple diseases with a single injection, making them highly desirable for comprehensive disease prevention and reducing the overall number of vaccinations needed, thereby driving the growth of the medication segment in market.
   
• Also, combining multiple antigens into a single vaccine can lower production, storage, and transportation costs, making these vaccines more cost-effective for healthcare systems and organizations.
   
• Furthermore, by reducing the number of injections, multivalent vaccines improve compliance among parents and caregivers, leading to higher vaccination rates and better herd immunity, thereby driving future growth in the market.

Based on the technology, the global pediatric vaccines market is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, conjugate vaccines, and other technologies. The inactivate vaccines segment dominated the market with market share of 29.3% in 2023.
 

• Inactivated vaccines which contain killed or inactivated pathogens are considered safer, especially for immunocompromised children, as they cannot cause the disease they are designed to protect against.
   
• Moreover, ongoing advancements in vaccine technology including improvements in adjuvants and delivery systems enhance the effectiveness and acceptance of inactivated vaccines, thereby fuelling the market growth.
   
• Furthermore, the global improvement in cold chain logistics and infrastructure ensures the effective storage and distribution of inactivated vaccines, especially in developing regions. Such aforementioned factor is expected to spur the segmental growth during the analysis period.
   

Based on indication, the pediatric vaccines market is classified into influenza, human papilloma virus, measles, mumps, and rubella, polio, pneumococcal disease, diphtheria, pertussis, and tetanus, and other indications. The influenza segment is expected to reach USD 33.3 billion by end of 2032.
 

• Influenza (flu) is a highly contagious respiratory illness that affects a significant number of children each year, especially during the flu season. The seasonal nature of influenza drives regular demand for influenza vaccines. Also, continuous improvements in influenza vaccine formulations such as the development of quadrivalent vaccines that offer broader protection against multiple strains, attract more consumers and healthcare providers.
   
• Furthermore, increasing awareness among parents and healthcare providers pertaining to the importance of influenza vaccination for children boosts demand, thereby contributing the market growth.
   

Based on end-use, the pediatric vaccines market is classified into public and private. The public segment is expected to exhibit 9.2% CAGR between 2024 - 2032.
 

• Government hospitals are often at the forefront of public health initiatives aimed at increasing vaccination rates among children. These initiatives include awareness campaigns, outreach programs, and school-based vaccination drives.
   
• Moreover, government hospitals often have established healthcare infrastructure and logistical capabilities that enable efficient storage, handling, and distribution of vaccines. This infrastructure supports the smooth implementation of immunization programs.
   
• Furthermore, government hospitals focus on ensuring equitable access to vaccines, particularly for underserved populations and remote areas. This commitment to health equity enhances vaccine coverage and supports market growth by reaching more children in need.

In 2023, North America secured a substantial market share of 48.2% in the global pediatric vaccines market and is expected to dominate throughout the forecast period.
 

• North America has a strong presence of major pharmaceutical and biotechnology companies, driving innovation and development of new vaccines and vaccine technologies. These companies invest heavily in R&D activities to bring new vaccines to the market.
   
• Moreover, strong public awareness campaigns and educational initiatives about the benefits of vaccination encourage high vaccination uptake rates among parents and caregivers supports market growth.  
   
• In addition, collaborations between academia, pharmaceutical companies, and government agencies drive innovation in pediatric vaccines, leading to the development of new vaccines and improvements in existing ones, thereby contributing the growth of the market in the U.S.
   

Germany to experience the highest growth rate in the Europe pediatric vaccines market.
 

• Germany has a well-established healthcare system with strong government policies supporting vaccination programs. Comprehensive coverage under statutory health insurance encourages high vaccination rates among children, thereby fostering the market growth.
   
• Moreover, extensive public health campaigns and education programs emphasize the importance of childhood immunization, increasing parental acceptance and demand for vaccines play a significant role in country level market growth.
   

The Asia Pacific pediatric vaccines market is expected to grow with a significant CAGR of 9.3% during the forecast period.
 

• Rapid population growth in Asia-Pacific region particularly in urban areas increases the demand for vaccines to protect against infectious diseases, as the region comprises higher population density and increased disease transmission risk. Also, strong government commitment to immunization programs and initiatives aimed at expanding vaccine coverage and access, often supported by international organizations such as WHO and UNICEF will help to achieve complete vaccination to population. Such aforementioned factor is expected to augment the regional market growth.
   

Pediatric Vaccines Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their product offerings, expanding their geographic reach, and investing in advanced technologies.
 

Pediatric Vaccines Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• Astellas Pharma, Inc.
• AstraZeneca Plc
• CSL Limited
• Daiichi Sankyo Company Limited
• Emergent BioSolutions, Inc,
• GlaxoSmithKline Plc
• Grifol SA
• Meissa Vaccines, Inc.
• Merck & Co. Inc.
• Panacea Biotec
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India
• Takeda Pharmaceutical Industries Limited
   

Pediatric Vaccines Industry News:

• In August 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. This helped the company expand its product offerings.
   
• In April 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20 for the prevention of invasive pneumococcal disease (IPD). This approval aimed to broaden the treatment availability, complementing existing vaccines for pneumococcal disease in children.
   

The pediatric vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Monovalent vaccines
• Multivalent vaccines

Market, By Technology

• Live attenuated vaccine
• Inactivate vaccine
• Toxoid vaccine
• Conjugate vaccine
• Other technologies

Market, By Indication

• Influenza
• Human papilloma virus
• Measles, mumps, and rubella
• Polio
• Pneumococcal disease
• Diphtheria, pertussis, and tetanus
• Other indications

Market, By End-use

• Public
• Private

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa